A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs

Jeffrey J. Sutherland, Dimitar Yonchev, Alexander Fekete and Laszlo Urban ()
Additional contact information
Jeffrey J. Sutherland: Novartis Institutes for Biomedical Research
Dimitar Yonchev: Novartis Institutes for Biomedical Research
Alexander Fekete: Novartis Institutes for Biomedical Research
Laszlo Urban: Novartis Institutes for Biomedical Research

Nature Communications, 2023, vol. 14, issue 1, 1-17

Abstract: Abstract In vitro secondary pharmacology assays are an important tool for predicting clinical adverse drug reactions (ADRs) of investigational drugs. We created the Secondary Pharmacology Database (SPD) by testing 1958 drugs using 200 assays to validate target-ADR associations. Compared to public and subscription resources, 95% of all and 36% of active (AC50

Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-40064-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-40064-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-40064-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().